Phase I single ascending dose trial of RSLV 132 in volunteers
Phase of Trial: Phase I
Latest Information Update: 16 Jul 2014
Price : $35 *
At a glance
- Drugs RSLV 132 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Resolve Therapeutics
- 16 Jul 2014 Status changed from recruiting to completed according to a Resolve Therapeutics media release.
- 17 Mar 2014 Status changed from planning to recruiting based on information reported in a Resolve Therapeutics media release.
- 20 Nov 2012 New trial record